BTIG Rates Kazia Therapeutics (KZIA) buy, $34 Price Target
BTIG reaffirms its buy rating on Kazia Therapeutics, maintaining a price target of $34, a 141.48% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BTIG rated Kazia Therapeutics Limited ($KZIA) "buy" with a $34 price target on July 1, 2026.
Since the rating, $KZIA is down 7.0% after 1 week, down 5.8% after 1 month and down 45.9% to date (from the $13.39 close on Jul 1, 2026).
KZIA
Kazia Therapeutics Limited
Key Points
- BTIG analyst Kambiz Yazdi reiterated a buy rating on Kazia Therapeutics, setting a price target of $34.
- BTIG's $34 price target implies 141.48% upside from Kazia Therapeutics Limited's ($KZIA) current $14.08 share price.
- Kazia Therapeutics shares traded at $14.08 on Wednesday, with a market cap of approximately $160.9 million.
- Insiders at Kazia Therapeutics recently bought shares, and other analysts have set targets ranging from $18 to $32.
Get $KZIA trade alerts by text
We text you when insiders, Congress or big funds trade $KZIA. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Kazia Therapeutics Limited alert may contain errors. Disclosures
BTIG has reiterated its buy rating on Kazia Therapeutics Limited (NasdaqCM:KZIA), setting a price target of $34. This reaffirmation by analyst Kambiz Yazdi was made on July 1, 2026. Shares of Kazia traded at $14.08 on Wednesday.
BTIG vs. the S&P 500
Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.
Kazia Therapeutics Limited Stock Up 35.5%
Shares of NasdaqCM:KZIA traded near $14.08 on Wednesday. Kazia Therapeutics has a market cap of about $160.9 million and a beta of 2.181, indicating it is more volatile than the overall market. The stock's 52-week range has been between $4.86 and $17.4, with a 50-day moving average of $12.87 and a 200-day moving average of $9.10.
$KZIA price target
Kazia Therapeutics Limited daily closes and this analyst's $34 target. Not advice.
Insider Buying and Selling at Kazia Therapeutics Limited
Recent insider activity at Kazia Therapeutics saw Chief Scientific Officer Sudha Rao and Chief Financial Officer James Levine each purchasing 250,000 and 200,000 shares, respectively, on June 19, 2026. These transactions were not part of a pre-arranged trading plan.
Analysts Set New Price Targets
On July 1, 2026, BTIG reiterated its buy rating on Kazia Therapeutics with a price target of $34. Previously, Lake Street initiated coverage with a buy rating and a $32 target on June 11, 2026. Laidlaw & Co. also initiated coverage with a buy rating and a $25 target on April 15, 2026. The consensus among analysts is a buy rating, with an average target price of approximately $25.44 based on four analyst opinions.
About Kazia Therapeutics
Kazia Therapeutics Limited is a biotechnology company based in Sydney, Australia. It focuses on developing cancer treatments, with its lead product, paxalisib, targeting various brain cancers. The company is also working on EVT801, aimed at treating advanced solid tumors. Kazia collaborates with several research groups and companies to further its drug development efforts. The company operates with a small team of six employees and is led by CEO Dr. John Edwin Friend II.
Bottom Line
BTIG's reaffirmation of a buy rating for Kazia Therapeutics, along with a $34 target, highlights continued interest in the company's potential. Investors should note that analyst ratings are based on projections and should consider the company's financials and market conditions. Kazia's insider buying activity and collaborations in the biotechnology sector are points of interest for stakeholders.
Related Filing Alerts
Source: BTIG's rating change on $KZIA (Jul 1, 2026). Written by software, not financial advice. How we make alerts